Stocks and InvestingStocks and Investing
Thu, March 10, 2022
Wed, March 9, 2022
Tue, March 8, 2022
Mon, March 7, 2022

Gena Wang Downgraded (BLUE) to Sell and Decreased Target to $4 on, Mar 7th, 2022


Published on 2024-10-27 19:58:52 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Downgraded "bluebird bio, Inc." (BLUE) to Sell and Decreased Target from $13 to $4 on, Mar 7th, 2022.

Gena has made no other calls on BLUE in the last 4 months.



There is 1 other peer that has a rating on BLUE. Out of the 1 peers that are also analyzing BLUE, 0 agree with Gena's Rating of Hold.



This is the rating of the analyst that currently disagrees with Gena


  • Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $10 on, Monday, November 8th, 2021